Christopher Schaber, president and CEO of Dor BioPharma, said: “We are pleased with the Therapeutics Goods Administration’s decision to grant orBec orphan drug designation for the treatment of gastrointestinal graft-versus-host-disease (GI GVHD).
“This bolsters our intellectual property position in Australia, which already includes issued and pending patents covering orBec in GI GVHD. It also potentially provides for a quicker path to regulatory approval in Australia once we have successfully completed our confirmatory Phase III clinical trial of orBec.”